Summary:
Alpine Clinical Research Center is conducting a phase III, 52 week, randomized, double-blind, 3-arm parallel
group study, comparing the efficacy, safety and tolerability of
the fixed dose triple combination FF/UMEC/VI with the fixed
dose dual combinations of FF/VI and UMEC/VI, all
administered once-daily in the morning via a dry powder inhaler
in subjects with chronic obstructive pulmonary disease
Qualified Participants Must:
• Be 40 years of age or older
•
Have a diagnosis of COPD
•
Be a current smoker or were a smoker in the past for at least 10 years
•
Have been on maintenance COPD medication for at least 3 months
•
Have 1 documented COPD exacerbation within 1 year prior to the first study visit
Qualified Participants May Receive:
Study medication and all study related costs as well as a small stipend will be provided.